Nutrition reviews · 2026
Effects of Pumpkin (Cucurbita spp.) on Glycemic and Type 2 Diabetes-Related Metabolic Biomarkers: A Systematic Review of Controlled Clinical Trials.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ye Ke, Cândido Flávia Galvão, Ramos Juliana de Souza, Guilarducci Mariana Julião, Guimarães Nathalia Sernizon, Liu Huaqing, Gomes Júnia Maria Geraldo
Аннотация
CONTEXT: Pumpkin (Cucurbita spp.) is a versatile, low-cost, widely used plant product with potential to promote glycemic control. However, clinical evidence regarding its antihyperglycemic efficacy remains inconsistent.
OBJECTIVE: The primary aim was to investigate the antihyperglycemic effects of pumpkin in human nutrition; the secondary aim was to assess pumpkin's impact on type 2 diabetes mellitus (T2DM)-related metabolic biomarkers.
DATA SOURCE: A systematic review was performed by searching databases (MEDLINE/PubMed, Embase, and Cochrane Library/Central) until March 2025 and included controlled clinical trials assessing the effects of pumpkin or its by-products on glucose outcomes and T2DM-related metabolic biomarkers in adults with or without T2DM.
DATA EXTRACTION: All studies were independently screened and extracted by 2 researchers. In the case of disagreement, a third researcher was consulted.
DATA ANALYSIS: From 198 records screened, 9 controlled clinical trials (n = 316 participants) were selected for qualitative analysis.
CONCLUSIONS: Pumpkin and its by-products have potential to be used as adjuvants in the prevention and/or treatment of T2DM. More high-quality and long-term clinical trials are needed to confirm this evidence.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration No. CRD42022376276.
OBJECTIVE: The primary aim was to investigate the antihyperglycemic effects of pumpkin in human nutrition; the secondary aim was to assess pumpkin's impact on type 2 diabetes mellitus (T2DM)-related metabolic biomarkers.
DATA SOURCE: A systematic review was performed by searching databases (MEDLINE/PubMed, Embase, and Cochrane Library/Central) until March 2025 and included controlled clinical trials assessing the effects of pumpkin or its by-products on glucose outcomes and T2DM-related metabolic biomarkers in adults with or without T2DM.
DATA EXTRACTION: All studies were independently screened and extracted by 2 researchers. In the case of disagreement, a third researcher was consulted.
DATA ANALYSIS: From 198 records screened, 9 controlled clinical trials (n = 316 participants) were selected for qualitative analysis.
CONCLUSIONS: Pumpkin and its by-products have potential to be used as adjuvants in the prevention and/or treatment of T2DM. More high-quality and long-term clinical trials are needed to confirm this evidence.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration No. CRD42022376276.